Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Review uri icon

Overview

abstract

  • Pancreatic neuroendocrine tumors are an uncommon tumor type and compose 1% to 2% of all pancreatic neoplasms. They are rarely localized at presentation and are typically diagnosed in the presence of metastatic disease. The management poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. A variety of systemic therapies have been developed for the management of pancreatic neuroendocrine tumors, including somatostatin analogues, a select group of cytotoxic chemotherapy agents, and targeted or biological agents. This article reviews the available systemic therapy options for advanced pancreatic neuroendocrine tumors.

publication date

  • October 23, 2015

Research

keywords

  • Antineoplastic Agents
  • Molecular Targeted Therapy
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms

Identity

PubMed Central ID

  • PMC5046222

Scopus Document Identifier

  • 84955181048

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2015.09.005

PubMed ID

  • 26614372

Additional Document Info

volume

  • 30

issue

  • 1